Search results for: 'water resources AND monitoring'

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

17 Jul 2017  |  North America  |  Market Research

US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

Infographics

×

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...

Operational, clinical, and financial challenges that result in inefficient resource utilization and suboptimal healthcare outcomes waste money and time and ultimately affect payers and providers’ ability to focus on preventive care and population health improvement. Frost & Sullivan defines population health management (PHM) as solutions and serv...

The hospital-at-home (HaH) care model provides hospital-grade care in a home setting for acute patients with conditions ranging from asthma and pneumonia to congestive heart failure. This analysis will cover market size and forecast at the solution level, including technological solutions and care coordination services for acute care management HaH...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...

07 Sep 2015  |  North America  |  Market Research

US Nucleic Acid Purification and Isolation Markets

Critical Sample Preparation Step Benefits from Downstream Applications

Infographics

×

The total market, as defined by this study, includes nucleic acid purification and isolation reagents (including kits and homebrew reagents) and nucleic acid purification and isolation instruments in the United States. The study period runs from 2011 to 2021, with 2014 as the base year and 2015–2021 as the forecast period. This research service off...

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...